VALBIOTIS (EPA:ALVAL)

BRIEF

published on 09/22/2026 at 17:45, 9 days 19 hours ago

Valbiotis announces positive results for Cardio-Liver and launches ValbiotisPRO® Liver

Valbiotis Metabolic Health Cardio-Liver Steadrive® ValbiotisPRO® Range
BRIEF

published on 09/22/2026 at 17:45, 9 days 19 hours ago

Valbiotis Announces Positive Results from Cardio-Liver Study

Clinical Research Liver Health Steadrive® Cardio-Liver Study ValbiotisPRO® Foie
PRESS RELEASE

published on 09/22/2026 at 17:40, 9 days 19 hours ago

VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23
Valbiotis announces positive results from Cardio-Liver study and commercial launch of ValbiotisPRO® Foie on September 23. Study confirms efficacy of Steadrive® on liver fat reduction

Valbiotis Clinical Trial Steadrive® Cardio-Liver Study ValbiotisPRO® Foie
BRIEF

published on 09/07/2026 at 17:50, 24 days 19 hours ago

VALBIOTIS: Update on voting rights and capital

Share Capital Voting Rights Euronext Growth Regulation Valbiotis
BRIEF

published on 08/17/2026 at 17:45, 1 month 15 days ago

VALBIOTIS SA: Update of voting rights and shares as of July 31, 2026

Voting Rights Actions Euronext Growth Threshold Crossing Valbiotis SA
BRIEF

published on 07/27/2026 at 17:45, 2 months 5 days ago

Valbiotis Applauds Cardiovascular Prevention Legislation

Valbiotis Healthcare Strategy French Legislation Cardiometabolic Health Cardiovascular Prevention
BRIEF

published on 07/27/2026 at 17:45, 2 months 5 days ago

Valbiotis welcomes the law on cardiovascular prevention

Valbiotis Screening Cardiometabolic Health Cardiovascular Prevention Pharmacist
PRESS RELEASE

published on 07/27/2026 at 17:40, 2 months 5 days ago

VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission
Valbiotis welcomes the final adoption of the Cardiovascular Prevention Act by the French Parliament, emphasizing prevention of cardiovascular and neurovascular diseases in France's national strategy

Healthcare Valbiotis Prevention Cardiovascular Prevention Act French Parliament
BRIEF

published on 07/22/2026 at 17:45, 2 months 10 days ago

Valbiotis' REVERSE-IT Study Gains International Recognition

Diabetes Management TOTUM•63 Nature Communications Cardiometabolic Health REVERSE-IT Study
BRIEF

published on 07/22/2026 at 17:45, 2 months 10 days ago

Publication of the results of the Valbiotis REVERSE-IT study

Diabetes Valbiotis Nature Communications REVERSE-IT Total•63

Published on 10/02/2026 at 12:45, 10 minutes ago

Gabriel Resources Announces US$3.4 Million Private Placement
Published on 10/02/2026 at 04:15, 8 hours 40 minutes ago

Torq Completes $529,000 Debt Settlement
Published on 10/02/2026 at 00:35, 12 hours 20 minutes ago

Medicure Announces Grant of Stock Options
Published on 10/02/2026 at 00:30, 12 hours 25 minutes ago

Immutable Holdings Provides Corporate Update
Published on 10/01/2026 at 23:05, 13 hours 50 minutes ago

Vox Royalty Expands Revolving Credit Facility Up to $150 Million and Strengthens Leadership Team

View all ACCESSWIRE

Published on 10/02/2026 at 11:40, 1 hour 14 minutes ago

Gunvor becomes Centalion
Published on 10/02/2026 at 11:35, 1 hour 19 minutes ago

One in Three: As Europe Goes Electric, VinFast Builds for the Long Term
Published on 10/02/2026 at 11:19, 1 hour 35 minutes ago

Custodian Property Income REIT plc: Director Declaration
Published on 10/02/2026 at 10:32, 2 hours 22 minutes ago

TVR-Total Voting Rights
Published on 10/02/2026 at 10:15, 2 hours 40 minutes ago

Tennor Global takes 65% stake in Alpha Energy's new international arm

View all EQS

Published on 10/01/2026 at 19:00, 17 hours 55 minutes ago

AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 18 hours 14 minutes ago

Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 18 hours 50 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 10/01/2026 at 18:00, 18 hours 54 minutes ago

Saint-Gobain completes the acquisition of Xypex (North America), a leader in high value-added waterproofing solutions
Published on 10/01/2026 at 17:55, 18 hours 59 minutes ago

Disclosure of transactions in own shares from September 28 to September 30, 2026

View all LES ECHOS COMFI WIRE

News